Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

NCT ID: NCT04577300

Last Updated: 2025-11-04

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-15
• Study Completion Date: 2026-08-15

Brief Summary

To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.

Detailed Description

A randomized, sham controlled, masked trial of up to 30 eyes will be recruited into the study. Participants with a qualifying study eye will be randomized after screening and baseline evaluations to receive 2 NT-501 ECT implants in the study eye (20 eyes), 1 NT-501 ECT implant (5 eyes) or a sham surgery (control arm; 5 eyes). No explant will be required. An examination for safety will occur one day and one week following implant and periodically thereafter for 24 months post-implant. Patients in the control arm may be offered 2 NT-501 ECT implants after the 12-month post-operative follow-up visit.

Conditions

Glaucoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Dual Implantation

Two NT-501 devices will be implanted in the study eye.

Group Type: EXPERIMENTAL

NT-501

Intervention Type: DRUG

Implant of Neurotech NT-501 device(s)

Single Implantation

One NT-501 device will be implanted in the study eye.

Group Type: EXPERIMENTAL

NT-501

Intervention Type: DRUG

Implant of Neurotech NT-501 device(s)

Sham Implantation

No NT-501 devices will be implanted in the study eye.

Group Type: SHAM_COMPARATOR

Sham comparator

Intervention Type: OTHER

Sham implantation

Interventions

NT-501

Implant of Neurotech NT-501 device(s)

Intervention Type: DRUG

Sham comparator

Sham implantation

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Participant must be medically able to undergo the testing required in the schedule of events (SOE).

2. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) of -3 to -20 dB on Humphrey Visual Field 24-2 testing and two visual field tests of adequate quality with a maximum VFI variability of ± 10%

3. Residual visual field preservation including best-corrected visual acuity (BCVA) better than 20/200 in either eye.

4. Participant's eye pressure must be clinically stable, with IOP <21.

5. If a participant has two eyes meeting study criteria, the worse eye as determined by visual field index (VFI) or patient preference, will be deemed includable. If both eyes qualify and have the same VFI, a randomization procedure will assign one eye to the study.

6. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.

7. Females of childbearing potential must agree to use an effective form of birth control.

8. Participant must be determined by the presurgical anesthesia or medical team to be fit for ophthalmic surgery for the NT-501 ECT implant insertion.

Exclusion Criteria

1. Participant is unable to comply with study procedures or followup visits.

2. Participant has other optic nerve or retinal degenerative disease causing vision loss, irrespective of whether it is currently treated or untreated.

3. Participant is likely to be offered glaucoma surgery in the study eye within 6 months of screening.

4. Participant has cataract-associated vision loss to less than 20/40.

5. Participant has a history of ocular herpes zoster.

6. Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.

7. Participant has evidence of corneal opacification or lack of optical clarity.

8. Participant has uveitis or other ocular inflammatory disease.

9. Participant is receiving systemic steroids or other immunosuppressive medications.

10. Participant has diabetic macular edema and/or diabetic retinopathy.

11. Participant has myopic degeneration.

12. Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.

13. Participant is pregnant or lactating.

14. Participant is on chemotherapy.

15. Participant has a history of malignancy other than basal cell carcinoma, unless it was treated successfully 2 years prior to inclusion in the trial.

16. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments.

17. Any intraocular surgery of the study eye within 12 weeks prior to the screening visit

18. History of use of drugs with known retinal toxicity, at retinotoxic doses.

19. Patient has a history of multiple sclerosis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Jeffrey L Goldberg

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jeffrey L Goldberg, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Byers Eye Institute at Stanford University

Palo Alto, California, United States

Countries

United States

Other Identifiers

56950

Identifier Type: -

Identifier Source: org_study_id